Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

J&J Highlights Late-Stage R&D Prospects Across Pharma Division

Jun 03 2013

• By Lisa LaMotta

Related Content

J&J’s Veridex To Lead Development Of Next-Gen Cancer Diagnostic

Jan 10 2011

The Future Of Oncology At J&J: An Interview With William Hait

Oct 17 2011

Pharmacyclics’ Ibrutinib Scoops Another FDA Breakthrough Designation, And Pfizer Joins The Club

Apr 15 2013

With Remicade Biosimilar On The Rise, J&J Adds Astellas’ JAK2 To Pipeline

Oct 04 2012

FDA Approves <em>Simponi</em> For Ulcerative Colitis

May 16 2013

Multiple Myeloma Market Snapshot: New Combos Offer Greater Longevity, But Payers May Push Back

May 13 2013

Related Companies

Johnson & Johnson

Johnson & Johnson

Pharmacyclics, Inc.

Abbott

Genmab A/S

ImmuNext Inc.

Wellspring Biosciences, Inc.

Phenex Pharmaceuticals AG

GSK plc

Astellas Pharma, Inc.

Additional Topics

Business Strategies Clinical Trials Personalized Medicine BioPharmaceutical Medical Device

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window